Jason Kolbert


Jason Kolbert Boosts Price Target for MannKind Corporation (MNKD) to $7; Here’s Why

Mannkind caught a price target boost from Maxim in the wake of a positive label revision for Afrezza.

What’s Holding Back MannKind Corporation’s (MNKD) Valuation? Maxim Sees a Company Poised for Growth

Analyst says MannKind’s Afrezza revenues can surpass debt, if investors can be patient for adoption.

Why Maxim Raised Price Target for Adamis Pharmaceuticals Corp

Adamis Stock Can Reach $13 as Symjepi Deal Is Imminent

Maxim Initiates Buy on Diagnostics Group Inc (IDXG); Sees 410% Upside for the Stock

Analyst Jason Kolbert of Maxim believes that Interpace Diagnostics Group Inc (NASDAQ:IDXG) has quite the upper hand over the leading market ruler Veracyte …

Maxim Sees Over 200% Upside for MannKind Corporation (MNKD)

  Shares of MannKind Corporation (NASDAQ:MNKD) are up nearly 3% in Friday trading session, as the inhaled insulin drug maker gets a vote …

AEterna Zentaris Inc. (USA) (AEZS) CEO’s Departure Raises Questions

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are tumbling nearly 7% in Monday’s trading session, following the news that CEO David Dodd is stepping …

Promising Future For Omeros Corporation (OMER) with Lead Drug Omidria?

Drug maker Omeros Corporation (NASDAQ:OMER) delivered solid results for its earnings report for the first quarter of the year 2017. In reaction, Maxim analyst Jason …

Here’s Why Maxim Slashed Price Target on Achillion Pharmaceuticals, Inc. (ACHN) Today

Maxim analyst Jason Kolbert slashes his price target on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to $5.

AEterna Zentaris Inc. (USA) (AEZS) Macrilen Is Back, Cheers Maxim

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are rising almost 8% today on the heels of indicating it intends to file a new drug …

Maxim Comments on Sophiris Bio Inc (SPHS) Ahead of Clinical Data Presentation at EU Urology Conference

In a research released Friday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Sophiris Bio Inc (NASDAQ:SPHS), with a price target …